Pharma News

The webinar was graced with the presence of Shri Vaidya Rajesh Kotecha, Secretary, Ministry of AYUSH, Govt. of India, Padma Bhushan Vd. Devendera Triguna, President of AMAM, All India Ayurvedic Congress and Ayurveda Mahasammelan, Shri Pramod Kumar Pathak, Additional Secretary, Ministry of AYUSH, Govt. of India, Dr. Manoj Nesari, Advisor (Ay.) Ministry of AYUSH, Govt. of India, Dr. D.C. Katoch, Advisor(Ay.) Ministry of AYUSH, Govt. of India, Dr.

India has come a long way by showing its capabilities & its manufactures have come a long way by showing their capacity, the capability to sustain all the odds & deliver the services. The government support through PLI Schemes has been a boom and indication that what government wants, deliberated Dr.

WuXi Biologics a global company with leading open-access biologics technology platforms, and Bayer, announced an acquisition deal, under which WuXi Biologics will take over and operate the Drug Substance (DS) facility at Bayer’s Wuppertal site. The companies also plan to enter into a long-term sublease agreement and a transition service contract. The volume of the transaction, including the sublease agreement, amounts to approximately 150 million euros. 

AstraZeneca and Amgen announced high-level results from the SOURCE Phase III trial which assessed the efficacy and safety of the potential new medicine tezepelumab compared to placebo in 150 severe asthma patients who required maintenance use of oral corticosteroids (OCS) on top of standard of care (SoC).

Pfizer and BioNTech SE announced that the European Commission (EC) has granted a conditional marketing authorization (CMA) to Pfizer and BioNTech for COMIRNATY® (also known as BNT162b2), for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine earlier today.